ROCKVILLE, Md., May 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter of 2024 and associated Company developments.
View original post here:
Supernus Announces First Quarter 2024 Financial Results
Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications
Go here to read the rest:
Seer Reports First Quarter 2024 Financial Results
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also intends to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of notes.
Read the original:
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing’s Syndrome Trial
Read the original post:
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
FREMONT, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the first quarter ended March 31, 2024.
Read more here:
Cytek Biosciences Reports First Quarter 2024 Financial Results
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
Read this article:
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced results for the three-month period ended March 31, 2024, and an overview of the Company’s progress.
Read this article:
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76
Follow this link:
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial -
See the rest here:
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall -